Clinical Research Directory

Inclusion Criteria: 1. Diagnosis of stage I-III breast cancer 2. 1-5 years post-treatment and currently disease free 3. Treatment involved adjuvant or neoadjuvant chemotherapy 4. Report cognitive problems of memory and concentration attributed to chemotherapy with a score of 10 or below on the FACT-Cog Impact on Quality of Life Scale (a score \~1SD below pre-chemotherapy treatment norms; this criterion was used in our prior R21 study, ensures a clinically meaningful level of cognitive concerns,41 and discriminates high and low PCI scores in prior research42) 5. Able to speak and read English 6. Age \>18 7. Able to provide IRB-approved written informed consent 8. Willing to use videoconferencing. Exclusion Criteria: 1. Previous CNS radiation, intrathecal therapy, or CNS-involved surgery 2. Previous cancer history with the exception of non-melanoma skin cancer 3. Previous exposure to chemotherapy with another cancer or due to other medical condition (e.g., methotrexate exposure for treatment of rheumatoid arthritis) 4. Significant neurodevelopmental, neurobehavioral, or medical risk factors likely to affect cognitive functioning (e.g., history of neurological disorder or TBI of greater than mild severity, such as loss of consciousness \>30 minutes, medical disorder that is unstable or likely to affect cognition such as metabolic disorder, heart attack or stroke, uncontrolled diabetes or endocrine dysfunction) 5. Currently meeting DSM-5 mental disorder criteria, including but not limited to neurodevelopmental, substance abuse, mood (e.g., Maj.Dep), anxiety, or psychotic disorders 6. Scoring 3 or below on the 6-item cognitive screen designed to detect severe memory disorders;43 7. Severe uncorrected sensory impairment (severe hearing or visual impairment)